Zhang et al. simultaneously delivered DOX and B-cell lymphoma-2-small interfering RNA(Bcl-2-siRNA) with an EGF-modified NPs (as shown in Table 2) to investigate their therapeutic effects on lung cancer (Zhang et al., 2016). Here, BCL2 is linked to lung carcinoma.